Biperiden


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Parkinsonism
Adult: As biperiden HCl: Initially, 2 mg 3-4 times daily, may increase according to response. Max: 16 mg/day.
Elderly: Lower initial dose and increase gradually to the lowest effective dose.

Oral
Drug-induced extrapyramidal symptoms
Adult: As biperiden HCl: 2 mg 1-3 times daily.
Elderly: Lower initial dose and increase gradually to the lowest effective dose.

Parenteral
Drug-induced extrapyramidal symptoms
Adult: As biperiden lactate: Up to 10-20 mg daily by IM or slow IV inj.
Elderly: Lower initial dose and increase gradually to the lowest effective dose.

Parenteral
Parkinsonism
Adult: As biperiden lactate: Up to 10-20 mg daily by IM or slow IV inj.
Elderly: Lower initial dose and increase gradually to the lowest effective dose.
Administration
Should be taken with food.
Contraindications
Untreated narrow-angle glaucoma, mechanical stenoses in the GI tract, paralytic ileus, megacolon, prostatic adenoma and diseases that can lead to perilous tachycardia.
Special Precautions
Patient w/ thyrotoxicosis, cardiac failure, tachycardia, and those at risk of convulsions. Avoid abrupt withdrawal. Elderly. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness, dizziness or blurred vision, if affected, do not drive or operate machinery.
Adverse Reactions
Urinary retention, dry mouth, constipation, nausea, vomiting, dyspepsia, blurred vision, mydriasis, dry eyes, tachycardia, arrhythmia, dizziness, drowsiness, headache, hallucinations, memory impairment, confusion, insomnia, worsening of dyskinesia, generalised choreic movements, fever due to anhidrosis, rash, flushed skin, dry skin, hypersensitivity reactions.
Overdosage
Symptoms: Mydriasis, dryness of mucous membranes, flushing, increased heart rate, reduced bowel motility, reduced ureter and bladder tone, increased temp, excitation, confusion, clouding of consciousness and/or hallucinations; cardiac and resp depression in severe overdosage. Management: Supportive treatment. Gastric lavage or emesis may be considered. May give acetylcholinesterase inhibitor as an antidote. Artificial ventilation, reduction of fever and application of a bladder emptying catheter may be necessary. May administer a cardiac stimulant (e.g. dobutamine) if cardiac depression occurs.
Drug Interactions
Increased CNS and peripheral side effects w/ anticholinergic psychotropic drugs, antihistamines, other antiparkinsonian drugs and antispasmodics. May potentiate dyskinesia w/ levodopa. Increased anticholinergic effects w/ quinidine. May reduce the effect of metoclopramide and other compounds w/ similar activity on the GI tract. May antagonise the therapeutic effects of anticholinesterases.
Food Interaction
Alcohol may enhance the CNS effects of biperiden.
Action
Biperiden is an anticholinergic agent w/ marked effect on the CNS which is important for its therapeutic application and has weak peripheral vegetative effects. The mechanism of action is considered to relate to competitive antagonism of acetylcholine at cholinergic receptors in the corpus striatum, which then restores the balance.
Absorption: Readily absorbed from the GI tract. Bioavailability: Approx 30%.
Metabolism: Undergoes extensive first-pass metabolism.
Excretion: Elimination half-life: Approx 20 hr.
Storage
Oral: Store between 15-30°C. Protect from light. Parenteral: Store between 15-30°C. Protect from light.
ATC Classification
N04AA02 - biperiden ; Belongs to the class of tertiary amines anticholinergic agents. Used in the management of Parkinson's disease.
Disclaimer: This information is independently developed by CIMS based on biperiden from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in